2,4-Dichloropyrido[3,4-d]pyrimidine (908240-50-6)
This product(s) resides on a APICMO contract.
The ability to produce, synthesize and manufacture large quantities of 2,4-Dichloropyrido[3,4-d]pyrimidine (908240-50-6) with quality control system under CGMP manufacturing
regulations.
Description
Dihydrofolate reductase (DHFR) has been a well-recognized target for the treatment of many diseases. Based on 8,10-dideazaminopterins, which are classical antifolates that potently inhibit DHFR, it is designed a series of novel 2,4-diamino-6-substituted pyrido[3,2-d]pyrimidines. By removing the glutamate moiety and introducing lipophilic groups, it was hoped to improve passive diffuse through the cell membranes. The target compounds were efficiently synthesized using one-pot procedure and evaluated in vitro for DHFR inhibition and antitumor activity.
Compounds 5e, 5h, 5i and 5k were the most potent inhibitors of recombinant human DHFR (rhDHFR) with IC50values in the range 0.2–1.0 μM. Analysis using flow cytometric indicated that the effect of compound 5k on cell cycle progression was linked to induction of S phase arrest. Compounds 5g, 5h, 5i and 5k showed broad spectrum antitumor activity against four different tumor cell lines, with IC50values in the range 0.07–23 μM. Molecular docking investigations showed that the trimethoyphenyl ring of compound 5k occupied a position near the cofactor-binding site in the rhDHFR-inhibitor complex, with close intermolecular contacts with Asp21, Phe31, Ser59, Ile60 and Pro61.
This product(s) resides on a APICMO contract. If you are viewing this page as a non-registered user, the price(s) displayed is List Price. To view your pricing, log in using your account number, or become a registered user by contacting one of our Customer Service teams. To place an order, contact APICMO Customer Service.
2,4-Dichloropyrido[3,4-d]pyrimidine (908240-50-6) Specifications
CAS | 908240-50-6 |
CAS Min % | 95% |
CAS Max % | 100% |
MDL Number | MFCD10699461 |
InChI Key | YJUVYWACDUJBDG-UHFFFAOYSA-N |
Chemical Name or Material | 2,4-Dichloropyrido[3,4-d]pyrimidine |
Infrared Spectrum | Authentic |
Physical Form | White to brown solid |
Packaging | Glass bottle |
Molecular Formula | C7H3Cl2N3 |
Molecular Weight (g/mol) | 200.02 |
SMILES | ClC1=NC2=CN=CC=C2C(Cl)=N1 |
Color | White |
Boiling Point | 340.821ºC at 760 mmHg |
Assay | 98% |
2,4-Dichloropyrido[3,4-d]pyrimidine (908240-50-6) Safety and Handling
- Do not breath dust or vapor.
- Have safety shower and eye wash available.
- Do not get in eyes, on skin or on clothing.
- Keep container tightly closed.
- Store in a cool, dry, well-ventilated place.
- Ensure adequate ventilation during use.
- Use only in a chemical fume hood.
WARNING: The information provided on this web site was developed in compliance with European Union (EU) regulations and is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guide for safe handling and use. It is not to be considered as either a warranty or quality specification.
2,4-Dichloropyrido[3,4-d]pyrimidine (908240-50-6) Articles
Synthesis and biological evaluation of irreversible EGFR tyrosine kinase inhibitors containing pyrido[3,4-d]pyrimidine scaffold
In the present study, a new class of compounds containing pyrido[3,4-d]pyrimidine scaffold with an acrylamide moiety was designed as irreversible
Medicinal Chemistry 2018
Discovery and in vivo effects of novel human natriuretic peptide receptor A (NPR-A) agonists with improved activity for rat NPR-A
Natriuretic peptide receptor A (NPR-A) agonists were evaluated in vivo by optimizing the structure of quinazoline derivatives to improve agonistic activity
Bioorganic and Medicinal Chemistry 2017
Technical Service:
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
2,4-Dichloropyrido[3,4-d]pyrimidine (908240-50-6) Bulk Ordering & Pricing:
Need larger quantities for your development, manufacturing or research applications?